+
+
+

meet celularity

Celularity is a commercial-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.

Backed by 100+ years of combined experience, our seasoned team of biopharmaceutical executives, scientists and clinicians has been integral to the success of numerous programs across discovery research, clinical development and commercialization in cancer immunotherapies and cell therapeutics. Everyone at Celularity is passionate about developing innovative treatment options that will make a meaningful difference in patients’ lives.

our pipeline

cell therapy pipeline

LEADERSHIP TEAM

BOBHARIRI

ROBERT J. HARIRI, MD, PHD

FOUNDER & CEO

Celgene, Weill Cornel Medicine

xiaokui-zhang

XIAOKUI ZHANG, PHD

EVP, CHIEF SCIENTIFIC OFFICER

Celgene, Rockefeller University

jay-kaminski

JAY KAMINSKI

CHIEF OPERATING OFFICER

Abbott, Celgene

nassirHabboubi

NASSIR HABBOUBI, MD

EVP, CHIEF MEDICAL OFFICER

Sanofi, Novartis

john-haines

JOHN R. HAINES

EVP, CHIEF ADMINISTRATIVE OFFICER

Andiscern, Ionetix, University of Pennsylvania

gertjanBartlema

GERTJAN BARTLEMA

EVP, CORPORATE STRATEGY & BUSINESS DEVELOPMENT

Amgen, Celgene

timothy-smith

TIMOTHY L. SMITH, JD PHD

EVP, GENERAL COUNSEL

Human Longevity, Novartis

BOARD OF DIRECTORS

peter-diamandis

PETER DIAMANDIS, MD

VICE CHAIR

Founder & Executive Chairman, XPRIZE; Executive Founder, Singularity University

henri-ji

HENRI JI, PhD

BOARD MEMBER

Co-Founder & CEO, Sorrento Therapeutics

davidLemus

DAVID LEMUS

BOARD MEMBER

Chief Executive Officer, Principal – LEMAX LLC

bill-maris

BILL MARIS

BOARD MEMBER

Founder, Section 32

andrew-pecora

ANDREW PECORA, MD, FACP, CPE

BOARD MEMBER

Chief Innovation Officer, John Thereur Cancer Center

john-sculley

JOHN SCULLEY

VICE CHAIR

Former CEO of Apple Inc; Former President of Pepsi-Cola

jaisim-shah

JAISIM SHAH

BOARD MEMBER

Chief Executive Officer, Senmur Pharmaceuticals

andrew-c-von-eschenbach

ANDREW C. VON ESCHENBACH, MD

BOARD MEMBER

Former Commissioner, United States FDA

newsroom

First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting

February 27, 2019

Read More

Celularity Acquires CariCord, Inc., Adds Important Biosourcing Assets, Strategic Relationship with the University of Colorado's ClinImmune Labs

August 31, 2018

Read More

Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration

February 15, 2018

Read More

join us

To view opportunities at celularity click here

contact us

Celularity, Inc.

33 Technology Drive

Warren, NJ 07059

For Investor Inquiries: john.haines@celularity.com

For Media Inquiries: media@celularity.com

Privacy Policy           |         Terms of Use